Yamanaka Kazuaki, Kakuta Yoichi, Miyagawa Shuji, Nakazawa Shigeaki, Kato Taigo, Abe Toyofumi, Imamura Ryoichi, Okumi Masayoshi, Maeda Akira, Okuyama Hiroomi, Mizuno Masashi, Nonomura Norio
Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Division of Organ Transplantation, Department of Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
PLoS One. 2016 Feb 29;11(2):e0148881. doi: 10.1371/journal.pone.0148881. eCollection 2016.
The association of complement with the progression of acute T cell mediated rejection (ATCMR) is not well understood. We investigated the production of complement components and the expression of complement regulatory proteins (Cregs) in acute T-cell mediated rejection using rat and human renal allografts.
We prepared rat allograft and syngeneic graft models of renal transplantation. The expression of Complement components and Cregs was assessed in the rat grafts using quantitative real-time PCR (qRT-PCR) and immunofluorescent staining. We also administered anti-Crry and anti-CD59 antibodies to the rat allograft model. Further, we assessed the relationship between the expression of membrane cofactor protein (MCP) by immunohistochemical staining in human renal grafts and their clinical course.
qRT-PCR results showed that the expression of Cregs, CD59 and rodent-specific complement regulator complement receptor 1-related gene/protein-y (Crry), was diminished in the rat allograft model especially on day 5 after transplantation in comparison with the syngeneic model. In contrast, the expression of complement components and receptors: C3, C3a receptor, C5a receptor, Factor B, C9, C1q, was increased, but not the expression of C4 and C5, indicating a possible activation of the alternative pathway. When anti-Crry and anti-CD59 mAbs were administered to the allograft, the survival period for each group was shortened. In the human ATCMR cases, the group with higher MCP expression in the grafts showed improved serum creatinine levels after the ATCMR treatment as well as a better 5-year graft survival rate.
We conclude that the expression of Cregs in allografts is connected with ATCMR. Our results suggest that controlling complement activation in renal grafts can be a new strategy for the treatment of ATCMR.
补体与急性T细胞介导的排斥反应(ATCMR)进展之间的关联尚未完全明确。我们使用大鼠和人类肾移植模型,研究了急性T细胞介导的排斥反应中补体成分的产生及补体调节蛋白(Cregs)的表达情况。
我们制备了大鼠肾移植同种异体移植和同基因移植模型。使用定量实时聚合酶链反应(qRT-PCR)和免疫荧光染色评估大鼠移植肾中补体成分和Cregs的表达。我们还向大鼠同种异体移植模型中注射抗Crry和抗CD59抗体。此外,我们通过免疫组织化学染色评估人类肾移植中膜辅助蛋白(MCP)的表达与其临床病程之间的关系。
qRT-PCR结果显示,与同基因模型相比,大鼠同种异体移植模型中Cregs、CD59和啮齿动物特异性补体调节因子补体受体1相关基因/蛋白-y(Crry)的表达降低,尤其是在移植后第5天。相反,补体成分和受体C3、C3a受体、C5a受体、B因子、C9、C1q的表达增加,但C4和C5的表达未增加,这表明替代途径可能被激活。当向同种异体移植肾注射抗Crry和抗CD59单克隆抗体时,每组的生存期均缩短。在人类ATCMR病例中,移植肾中MCP表达较高的组在ATCMR治疗后血清肌酐水平有所改善,且5年移植肾存活率更高。
我们得出结论,同种异体移植中Cregs的表达与ATCMR相关。我们的结果表明,控制肾移植中的补体激活可能是治疗ATCMR的一种新策略。